Osteoinductive potential of recombinant BMP-9 in bone defects of mice treated with antiresorptive agents

Hanley, 2012, Denosumab: mechanism of action and clinical outcomes, Int J Clin Pract, 66, 1139, 10.1111/ijcp.12022 Khojasteh, 2013, Effects of different growth factors and carriers on bone regeneration: a systematic review, Oral Surg Oral Med Oral Pathol Oral Radiol, 116, e405, 10.1016/j.oooo.2012.01.044 Carreira, 2014, Bone morphogenetic proteins: facts, challenges, and future perspectives, J Dent Res, 93, 335, 10.1177/0022034513518561 Fujioka-Kobayashi, 2017, Osteogenic potential of rhBMP9 combined with a bovine-derived natural bone mineral scaffold compared to rhBMP2, Clin Oral Implants Res, 28, 381, 10.1111/clr.12804 Fujioka-Kobayashi, 2017, Recombinant human bone morphogenetic protein (rhBMP)9 induces osteoblast differentiation when combined with demineralized freeze-dried bone allografts (DFDBAs) or biphasic calcium phosphate (BCP), Clin Oral Investig, 21, 1883, 10.1007/s00784-016-1983-0 Fujioka-Kobayashi, 2017, Growth factor delivery of BMP9 using a novel natural bovine bone graft with integrated atelo-collagen type I: Biosynthesis, characterization, and cell behavior, J Biomed Mater Res A, 105, 408, 10.1002/jbm.a.35921 Fujioka-Kobayashi, 2016, Recombinant human bone morphogenetic protein 9 (rhBMP9) induced osteoblastic behavior on a collagen membrane compared with rhBMP2, J Periodontol, 87, e101, 10.1902/jop.2016.150561 Fujioka-Kobayashi, 2018, Superior bone-inducing potential of rhBMP9 compared to rhBMP2, J Biomed Mater Res A, 106, 1561, 10.1002/jbm.a.36359 Sreekumar, 2017, BMP9 a possible alternative drug for the recently withdrawn BMP7? New perspectives for (re-)implementation by personalized medicine, Arch Toxicol, 91, 1353, 10.1007/s00204-016-1796-6 Savaridas, 2013, Do bisphosphonates inhibit direct fracture healing? A laboratory investigation using an animal model, Bone Joint J, 95, 1263, 10.1302/0301-620X.95B9.31562 Nagashima, 2005, Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur, Bone, 36, 502, 10.1016/j.bone.2004.11.013 Furuya, 2011, Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts, J Biol Chem, 286, 37023, 10.1074/jbc.M111.246280 Hadjidakis, 2006, Bone remodeling, Ann N Y Acad Sci, 1092, 385, 10.1196/annals.1365.035 Fong, 2013, Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro, Cell Signal, 25, 717, 10.1016/j.cellsig.2012.12.003 Erdfelder, 1996, GPOWER: A general power analysis program, Behav Res Methods Instrum Comput, 28, 1, 10.3758/BF03203630 Bougioukli, 2016, Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect, Bone, 84, 93, 10.1016/j.bone.2015.12.052 Fujioka-Kobayashi, 2012, Cholesteryl group- and acryloyl group-bearing pullulan nanogel to deliver BMP2 and FGF18 for bone tissue engineering, Biomaterials, 33, 7613, 10.1016/j.biomaterials.2012.06.075 Kawamoto, 2014, Preparation of thin frozen sections from nonfixed and undecalcified hard tissues using Kawamot’s film method (2012), 149 Kostenuik, 2011, Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody, Bone, 49, 151, 10.1016/j.bone.2011.03.769 Ominsky, 2011, Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys, Bone, 49, 162, 10.1016/j.bone.2011.04.001 Kostenuik, 2009, Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, J Bone Miner Res, 24, 182, 10.1359/jbmr.081112 Gerstenfeld, 2009, Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing, J Bone Miner Res, 24, 196, 10.1359/jbmr.081113 Yasuda, 2013, RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases, World J Orthop, 4, 207, 10.5312/wjo.v4.i4.207 Yang, 2014, Bone morphogenetic proteins: Relationship between molecular structure and their osteogenic activity, Food Sci Human Wellness, 3, 127, 10.1016/j.fshw.2014.12.002 Nakamura, 2013, Co-stimulation with bone morphogenetic protein-9 and FK506 induces remarkable osteoblastic differentiation in rat dedifferentiated fat cells, Biochem Biophys Res Commun, 440, 289, 10.1016/j.bbrc.2013.09.073